diabetologia

name

diabetologia

description

Use when targeting Diabetologia or deciding whether a diabetes clinical, epidemiological, or basic/translational study fits this venue. Encodes the journal's diabetes-focused fit across the evidence spectrum, the mechanistic and methodological bar, reporting-guideline and registration requirements, EASD house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice.

Diabetologia (diabetologia)

Journal positioning

Diabetologia is the flagship journal of the European Association for the Study of Diabetes (EASD), publishing diabetes-focused research across the full evidence spectrum — clinical and pragmatic trials, epidemiology and population science, and basic/translational science of islet biology, insulin action, complications, and metabolism. Unlike a broad endocrine journal, Diabetologia is diabetes-dedicated and explicitly welcomes rigorous basic and mechanistic science (beta-cell biology, insulin signaling, animal/cell models) alongside human clinical and epidemiologic work. Its defining expectation is a significant advance in understanding, preventing, treating, or explaining diabetes and its complications, not a small descriptive series or an association study with no mechanistic or clinical payoff. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live Diabetologia author instructions.

When to trigger

• The author names Diabetologia for a diabetes clinical, epidemiological, or basic/translational study and wants a fit/framing check.
• A diabetes study must be re-framed around a mechanism, a prevention/treatment question, or a complications-outcome question.
• The author is choosing between Diabetologia (diabetes-specific, incl. basic science), JCEM (broad endocrine), and The Lancet Diabetes & Endocrinology (high-impact trials).
• The author needs the journal's reporting-guideline, registration, and basic/animal-study expectations for diabetes research.

Scope & topic fit

• Type 1 and type 2 diabetes: pathogenesis, prevention, glucose-lowering therapy, and management trials.
• Diabetes epidemiology and population science: incidence, risk factors, and outcomes across cohorts.
• Islet and beta-cell biology, insulin secretion and action, and metabolic mechanism in cells and animal models.
• Diabetic complications: nephropathy, retinopathy, neuropathy, and cardiovascular disease in diabetes, with mechanism or outcome rigor.
• Gestational diabetes, monogenic diabetes, and metabolic phenotyping studies.
• Diabetes biomarkers, genetics/genomics, and -omics with disease relevance and validation.

Method & evidence bar

• Clinical studies must be adequately powered with prespecified, patient-centered diabetes endpoints; trials require prospective registration and the registration number.
• The applicable reporting guideline and checklist are expected: CONSORT for trials, STROBE for observational/epidemiologic work, PRISMA for systematic reviews, ARRIVE for animal studies.
• Basic/translational work needs rigorous controls, biological replication, validated reagents/models, and blinded/randomized animal experiments where applicable.
• Mechanistic claims require perturbation evidence and, where feasible, anchoring to human islets, tissue, or cohorts; glucose/insulin-clamp and metabolic methods must be described.
• Epidemiologic claims must address confounding, bias, and generalizability; causal language must match the design.
• Effect estimates need confidence intervals and absolute as well as relative measures.

Structure & house style

• EASD/Springer format with a structured abstract (aims/hypothesis, methods, results, conclusions) and a research-in-context/significance statement; re-check current article types and limits on the live guide.
• The introduction frames the diabetes-biology or clinical gap; the discussion states the mechanistic or practice implication and bounds overreach.
• A CONSORT/STROBE/PRISMA flow diagram is expected for the relevant clinical design; animal work reports ARRIVE-aligned detail.
• Figures show representative data with statistics, N, and replication; an electronic supplement carries full methods, the protocol/SAP, and additional experiments.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and ../../resources/official-source-map.md; start from the ICMJE/EQUATOR and EASD/Springer anchors, then cite the current Diabetologia page you checked.
• Search the live site for "Diabetologia EASD instructions for authors" and follow the current version.
• Re-check article types, abstract structure and research-in-context format, and word/figure/reference limits.
• Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE), data/code-availability, and protocol/SAP submission.
• Re-check IRB/ethics and consent, animal-care/IACUC approval, ICMJE authorship and conflict-of-interest disclosure, funding, and AI-use disclosure.
• If the live official instructions conflict with this skill, the official instructions win.

Pre-submission self-check

• The study delivers a clear diabetes mechanism, prevention/treatment, or complications advance.
• Clinical diabetes endpoints are prespecified and powered; trials are registered with the number in the manuscript.
• The correct reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE) is completed and attached.
• Basic/translational work shows controls, replication, model validation, and human anchoring.
• Epidemiologic claims address confounding and generalizability; causal language matches the design.
• IRB/consent, IACUC (if animal), ICMJE disclosures, and a data-availability statement are prepared.

Common desk-reject triggers

• Small descriptive diabetes series or registry slice with no mechanism and no clinical payoff.
• Association-only biomarker/-omics studies with no validation cohort or functional follow-up.
• Animal/cell diabetes work without human relevance, replication, or ARRIVE-aligned rigor.
• Missing trial registration, protocol, or the required reporting checklist.
• Broad endocrine scope diluting the diabetes focus, better placed in a generalist endocrine venue.

Re-routing decision

• Broad endocrine (thyroid/adrenal/bone/reproductive) beyond diabetes → journal-of-clinical-endocrinology-and-metabolism.
• High-impact diabetes/endocrine trial with broad reach → the-lancet-diabetes-and-endocrinology.
• Diabetic kidney disease centered on nephrology mechanism/outcomes → journal-of-the-american-society-of-nephrology / kidney-international.
• Obstetric/gestational-diabetes pregnancy outcomes → american-journal-of-obstetrics-and-gynecology.
• Broad practice-changing diabetes trial → general medicine (jama / NEJM / The Lancet in the natural-science bundle).

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] Diabetologia (EASD)
[Specialty tags] <T1D / T2D / islet biology / complications / epidemiology + clinical/basic>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / animal-ARRIVE>
[Method/evidence] <power, mechanism, controls/replication, registration>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / IACUC / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>